Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06373380 | A Study of HB-202/HB-201 in People With Human Papilloma Virus 16-Positive Head and Neck Squamous Cell Cancer (HPV 16+ HNSCC) | EARLY_PHASE1 | ACTIVE NOT_RECRUITING | 7 | — | — | Apr 15, 2024 | Apr 1, 2027 | Jan 20, 2026 | 7 | United States |
Patients who have received at least one dose of treatment will be considered evaluable. Origin time point will be from start of treatment.
| Arm | Type | Description |
|---|---|---|
| HB-200 arm | EXPERIMENTAL | HB-202 and HB-201 will be given in an alternating fashion for 4 total treatments. |
| Name | Type | Description |
|---|---|---|
| HB-200 | DRUG | HB-200 arm will receive HB-202 and HB-201 (HB-202: 1 x 10 \^7 RCV FFU and HB201: 5 x 106 RCV FFU) in an alternating fashion every (21 days) intravenously for 4 doses (2 doses each of HB-202 and HB-201 alternating). |
Inclusion Criteria: * Pathologically (histologically or cytologically) proven diagnosis of HPV16+ squamous cell carcinoma of the head and neck post standard of care definitive therapy. * History of histologically confirmed HPV16+ squamous cell cancer (from in-house or local evaluation by HPV16 R...